Novel Agent for Major Depression Moves to Phase III, Even With Setback

(MedPage Today) — Despite missing the primary endpoint, the novel KV7 potassium channel opener azetukalner showed benefit in major depressive disorder (MDD) in the phase II, proof-of-concept, randomized X-NOVA trial.
While the mean reduction…

Source link : https://www.medpagetoday.com/psychiatry/depression/115761

Author :

Publish date : 2025-05-27 15:21:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Novel Agent for Major Depression Moves to Phase III, Even With Setback

Maternal Mental Health Declines Sharply Over 8 Years

CDC Ends COVID Vaccine Recs for Healthy Kids, Pregnant Women

Related Posts

Our big brains may have evolved because of placental sex hormones

Leeds maternity services now ‘inadequate’ after inspectors act on parents’ concerns

Early, Aggressive BP Lowering Tied to Better ICH Outcomes

Warning for Hepatitis C Care; MASLD Deaths to Double; EHR Frustration for IBD Docs

Your brain tracks your sleep debt – and now we may know how

CAR T-cell therapy could be made in the body of someone with cancer

Our big brains may have evolved because of placental sex hormones

Leeds maternity services now ‘inadequate’ after inspectors act on parents’ concerns

Early, Aggressive BP Lowering Tied to Better ICH Outcomes

Warning for Hepatitis C Care; MASLD Deaths to Double; EHR Frustration for IBD Docs

Your brain tracks your sleep debt – and now we may know how

CAR T-cell therapy could be made in the body of someone with cancer

Being a Black Man in Medical School Takes a Toll

Ukrainian Trauma Surgeon: ‘Our Country Is Profoundly Exhausted’

Categories

Archives